Share on StockTwits

Illumina (NASDAQ:ILMN) Director Daniel Bradbury sold 2,100 shares of the stock on the open market in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $172.89, for a total value of $363,069.00. Following the sale, the director now directly owns 12,466 shares in the company, valued at approximately $2,155,247. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Illumina (NASDAQ:ILMN) traded up 2.51% during mid-day trading on Wednesday, hitting $175.23. The stock had a trading volume of 1,766,284 shares. Illumina has a 52-week low of $72.13 and a 52-week high of $184.49. The stock’s 50-day moving average is $168.9 and its 200-day moving average is $151.4. The company has a market cap of $22.499 billion and a P/E ratio of 120.21.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, April 22nd. The company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.01. The company had revenue of $421.00 million for the quarter, compared to the consensus estimate of $391.50 million. During the same quarter in the previous year, the company posted $0.46 earnings per share. The company’s revenue for the quarter was up 27.2% on a year-over-year basis. On average, analysts predict that Illumina will post $2.17 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Illumina from a “neutral” rating to an “outperform” rating in a research note on Tuesday, June 24th. They now have a $205.00 price target on the stock. Separately, analysts at Ned Davis Research upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. Finally, analysts at Maxim Group upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Wednesday, April 23rd. They now have a $205.00 price target on the stock. Six analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $150.97.

Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.